Kyrgyzstan Medical Device Nomenclature: GMDN Codes, Types and the National Register

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Kyrgyzstan uses the Global Medical Device Nomenclature (GMDN) to identify device types and assigns a registration number after registration, under which the device is entered into the national register of registered medical devices. Article 2 of Annex 1 to Cabinet of Ministers Resolution No. 513 simultaneously defines three hierarchical concepts: medical device type, model and nomenclature. The type (the GMDN code) determines what the product is, the model determines which specific variants exist within that family, and the nomenclature is the systematized classification list maintained at the national level. Together, the three concepts determine how many models a single registration dossier can contain. Misjudging the type-model structure is one of the most expensive planning errors a manufacturer can make, because it directly controls the number of dossiers, the fees and the total time to market.

2. Legal basis

  1. Resolution No. 513 of the Cabinet of Ministers, dated August 27, 2024, Annex 1, Article 2:
    • Global Medical Device Nomenclature (GMDN): a systematized nomenclature classification code used to identify medical devices;
    • Medical device type: a set of medical devices with the same or similar purpose and/or construction;
    • Model: a variety of medical device developed on the basis of the parent product, sharing common structural features with it, intended for improved, extended or specialized applications;
    • Nomenclature: a systematized nomenclature list containing type names, unique codes and type descriptions, including classification features by purpose and/or construction;
    • Registration number: the identifier assigned to a device upon registration, under which it is entered into the national register of registered medical devices of the Kyrgyz Republic.
  2. Annex 1 to Resolution No. 513, Article 1: the procedures cover the maintenance of the nomenclature and the national register.
  3. Law No. 216, Article 29: devices that have been registered and entered into the national register are imported on the basis of the register entry.

3. Expert insights

Insight 1: The GMDN code is an identity, not a formality.

Writing GMDN into the statutory definitions means it is the legal method of identifying the device. The practical consequence: choosing the wrong GMDN code places the product in the wrong type group, which in turn distorts the classification rationale, the testing plan and the review pathway. We recommend determining the GMDN code before drafting the classification rationale, rather than filling it in casually at the end of dossier preparation. A code chosen early anchors every downstream document; a code changed late forces revisions across the technical file, the application form and the labeling.

Insight 2: The two-level type-model structure determines the capacity of a dossier.

A type is a group of devices with the same or similar purpose and/or construction; a model is a variant developed from the parent product. One registration dossier normally corresponds to one type and contains multiple models. This means the decision to split a product line into several dossiers or to consolidate it into one depends on whether the products fall within the same GMDN type. Splitting wrongly or merging wrongly leads to additional time and cost. Mapping the entire product portfolio against GMDN types before filing is therefore a portfolio-level planning exercise, not a per-product clerical task.

Insight 3: Model changes require a new application, which makes forward planning a hard requirement.

A multilateral country survey explicitly records that when a device model is changed or improved, a re-registration application must be submitted, and components not included at initial registration must be registered separately. Combined with the type-model structure, the conclusion is direct: at first registration, all models and specifications expected to be launched within the next three years should be included in the same dossier, so that the cost of repeated registrations is absorbed once (see article 20 of this series). Treating the first registration as a portfolio event rather than a single-product event is the most effective way to control long-term regulatory spend in Kyrgyzstan.

Insight 4: The national register is the passport at the import stage.

Article 29 of Law No. 216 makes registration and entry into the national register the precondition for import on the basis of the register record. Registration and listing are two separate actions: after the certificate is issued, the data are entered into the register, and import clearance relies on the register entry. Companies should verify, immediately after receiving the certificate, that the register record matches the certificate content. If the model range recorded in the register is narrower than the range on the certificate, imports will still be blocked. Checking the register entry is a five-minute task that prevents a shipment-level crisis.

Insight 5: The nomenclature is maintained dynamically.

Article 1 of Annex 1 to Resolution No. 513 lists maintenance of the nomenclature as part of the procedures, which means the national nomenclature list will be updated over time. Companies running multi-product, multi-year programs should periodically re-check whether the GMDN codes they have used have changed and avoid letting new products inherit outdated codes. A simple internal ledger of codes, determination dates and determination rationale turns this from an ad hoc worry into a routine annual review item.

4. Practical recommendations

First, fix the GMDN code before the classification rationale. We recommend reversing the usual order: determine the GMDN code and type membership first, then build the risk class rationale under Decision No. 173. The two threads then corroborate each other and the classification conclusion is more robust under review.

Second, organize the product line by type and cover several years of models in one filing. At first registration, include in the same dossier all models of the same type expected within the next three years, and explain in the dossier the structural relationship of each model to the parent product and the differences between them.

Third, check the national register record immediately after certification. We recommend verifying five items: device name; type and model list; registration number; certificate holder; and authorized representative. Where the register record and the certificate diverge, apply for correction promptly, before the first import shipment is scheduled.

Fourth, maintain a GMDN code ledger with an annual review. Record the code, the determination date and the determination rationale for each product line, review the ledger annually, and track updates to the nomenclature list so that new filings never rely on stale codes.

5. Verification checklist

  • □ The GMDN code for each product has been determined, with the rationale and date recorded;
  • □ The type-model structure is defined: one dossier corresponds to one type containing all models to be registered;
  • □ The model list at first registration covers all specifications expected to be launched within three years;
  • □ After certification, the five register items were checked: device name, type and model list, registration number, holder, authorized representative;
  • □ A GMDN code ledger exists with an annual review mechanism;
  • □ Confirmed that import relies on the national register entry (Article 29 of Law No. 216).

Regulatory information verified as of October 29, 2026.

Our services cover: pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance support, post-market surveillance and device vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registration. We maintain a stable local cooperation network in Bishkek, Almaty, Tashkent and Moscow, work in Chinese, Russian and English, and provide executable solutions for foreign manufacturers on the issues most commonly encountered in CIS markets: authorized representative arrangements, notarization and legalization chains for powers of attorney, technical documentation localization, and inspection readiness. GRZAN supports manufacturers, importers and authorized representatives throughout the Kyrgyzstan registration lifecycle.

We adhere to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Any figure or timeframe that cannot be verified is labeled as a practical estimate and is never presented as a legal requirement.

For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail